You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Boehringer Ingelheim
Mallinckrodt
Express Scripts
McKinsey

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

FOSAPREPITANT DIMEGLUMINE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for fosaprepitant dimeglumine and what is the scope of patent protection?

Fosaprepitant dimeglumine is the generic ingredient in two branded drugs marketed by Merck And Co Inc, Apotex, Baxter Hlthcare Corp, Be Pharms, Fresenius Kabi Usa, Lupin Ltd, MSN, Mylan Labs Ltd, Sungen Pharma, and Teva Pharms Usa, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for fosaprepitant dimeglumine. Fourteen suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for FOSAPREPITANT DIMEGLUMINE

See drug prices for FOSAPREPITANT DIMEGLUMINE

Recent Clinical Trials for FOSAPREPITANT DIMEGLUMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of LahorePhase 3
Prof. Dr. Fridoon Jawad AhmadPhase 3
bahria international hospitalPhase 3

See all FOSAPREPITANT DIMEGLUMINE clinical trials

Generic filers with tentative approvals for FOSAPREPITANT DIMEGLUMINE
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial150MGINJECTABLE;INJECTION
  Start Trial  Start TrialUNKNOWNUNKNOWN

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE
Tradename Dosage Ingredient NDA Submissiondate
EMEND POWDER;INTRAVENOUS fosaprepitant dimeglumine 022023 2012-01-25

US Patents and Regulatory Information for FOSAPREPITANT DIMEGLUMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 211860-001 Sep 5, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Apotex FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 205020-001 Sep 5, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No   Start Trial   Start Trial   Start Trial
Be Pharms FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 212309-001 Sep 5, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Teva Pharms Usa FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 210064-001 Sep 5, 2019 RX No No   Start Trial   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FOSAPREPITANT DIMEGLUMINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Dow
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.